Please assess the completion status of the following clinical trial:

Trial Title: Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms suggestive of GERD, with heartburn as their predominant symptom (described as a burning feeling, rising from the stomach or lower part of the chest up towards the neck), for longer than 6 months.~* Heartburn occurring for 4 days or more during the last 7 days prior to endoscopy. Or, if PPI treatment has been started within the last 7 days prior to endoscopy, then heartburn occurring for 4 days or more during the last 7 days prior to start of PPI treatment~* Male or female, at least 18 years of age (for Austria, at least 19 years of age)~* Have given written informed consent~* Ability to read and write (literate)~* 7 symptom free (from heartburn) days in the last week prior to randomisation (day of visit not included)~Exclusion Criteria:~* Documented esophageal mucosal break~* History of esophageal, gastric or duodenal surgery, except closure and oversewing of an ulcer~* Chronic or recurrent abdominal pain associated with a chronic or recurrent bowel disturbance and/or bloating, that in the opinion of the investigator is likely to be due to irritable bowel syndrome or two or more of the following criteria:~  * Symptoms relieved by defecation~ * Symptoms associated with change in frequency of stools~ * Symptoms associated with change in form of stools~* Any significant alarm symptoms such as unintentional weight loss, haematemesis melaena, jaundice or any other sign indicating serious or malignant disease.~* Subjects with current or historical evidence of the following diseases/conditions~  * Zollinger Ellison syndrome~ * Primary esophageal motility disorder(s) i.e. achalasia, scleroderma, esophageal spasm~ * Complications of GERD such as esophageal stricture, ulcer and/or macroscopic Barrett's metaplasia (longer than 3 centimetres) or significant dysplastic changes in the esophagus~ * Evidence of upper gastrointestinal malignancy at the screening endoscopy~ * Gastric and/or duodenal ulcers within the last 2 years~ * Malabsorption~ * Malignancy, or significant cardiovascular, pulmonary, renal, pancreatic or liver disease as judged by the investigator~ * Unstable diabetes mellitus. Stable diabetes controlled on diet, oral agents or insulin is acceptable~ * Cerebrovascular disease, such as cerebral ischemia, infarction, haemorrhage or embolus~* Subjects using a PPI for more than 10 days in the last 28 days, prior to endoscopy~* Use of PPIs for more than 5 days in the last 7 days prior to endoscopy~* Subjects using daily H2-receptor antagonist, prokinetics recommended in the treatment of reflux symptoms or sucralfate during the 2 weeks prior to endoscopy and between the endoscopy and visit 1 and throughout the study~* Need for continuous concurrent therapy with~  * NSAIDs (including selective COX II antagonists, salicylates (unless\<165 mg daily for cardiovascular prophylaxis)~ * anticholinergics~ * prostaglandin analogues~ * phenytoin~ * ketoconazole~ * itraconazole~ * warfarin and other vitamin K antagonists~* Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator (for Austria: Women of child-bearing potential may only be included when their pregnancy status is assessed by the investigator prior to entry and then at monthly basis. For South-Africa and Spain:~Women of child-bearing potential may only be included when their pregnancy status is assessed by the investigator prior to endoscopy)~* Use of any other investigational compound 28 days prior to start and during the study~* Requirement of an interpreter (illiterate)~* Alcohol and/or drug abuse or any condition associated with poor compliance, including expected non-co-operation, as judged by the investigator~* Previous participation in this study~* Contra-indications to study drugs, e.g. known or suspected allergy to esomeprazole and any other constituents of the formulation. Known hypersensitivity to substituted benzimidazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On demand 20 mg esomeprazole (Type: EXPERIMENTAL): On demand treatment with 20-mg esomeprazole once daily when needed
- Continuous 20 mg esomeprazole (Type: ACTIVE_COMPARATOR): Continuous treatment with 20 mg esomeprazole once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).